Acute coronary syndrome
Conditions
Interventions
None listed
Sponsors
University of Fukui
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: Patients with dyslipidemia treated with statins Patients with LDL-C of 100 mg/dL or higher even with conventional therapy at the time of introduction of the drug used.
Exclusion criteria
Exclusion criteria: Patients who are already receiving a drug of the same type or a drug already being used before enrollment in the study. Patients who are not taking statin Patients with LDL-C less than 100 mg/dL Patients with contraindications to statins requiring concomitant use Patients with a history of hypersensitivity to any component of the drug used Patients whom the attending physician deems inappropriate for participation in the study on medical grounds Patients who are pregnant, lactating, may be pregnant, or wish to become pregnant during the study period.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Evaluation of biomarker variability (LDL, MMP9, PTX3, hs-CRP, TNF-alpha, L-arginine/ADMA Ratio, PCSK9 assessed at emergency PCI, 2 weeks, and 32-40 weeks post PCI) | — |
Secondary
| Measure | Time frame |
|---|---|
| Evaluation of vulnerable plaque (assessed by coronary angioscopy at 32-40 weeks post PCI) Inhibition of myocardial remodeling (evaluated by echocardiography within 48 hours and at 32-40 weeks post PCI) | — |
Countries
Japan
Contacts
Public ContactHiroyasu Uzui
University of Fukui Department of Cardiovascular Medicine
Outcome results
None listed